We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Feather Safety Razor

Download Mobile App





Transgenic Mouse That Models Immune Disease’s Cytokine Storms Could Point to Treatment Solution for COVID-19

By HospiMedica International staff writers
Posted on 05 Jun 2020
Print article
Image: This is a microscopic photo of a blood smear from a transgenic mouse that mimics the human immune disorder, secondary HLH (Photo courtesy of Cincinnati Children’s Hospital Medical Center)
Image: This is a microscopic photo of a blood smear from a transgenic mouse that mimics the human immune disorder, secondary HLH (Photo courtesy of Cincinnati Children’s Hospital Medical Center)
A transgenic mouse developed at Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) could play a key role in saving lives during the COVID-19 virus pandemic.

The so-called cytokine storm that inundates the bodies of severely ill COVID-19 patients with inflammatory cells produced by the immune system is a common feature of children battling secondary HLH, which happens in patients where initial HLH treatment has not worked. This common clinical feature of both illnesses was noticed by Gang Huang, PhD, one of the inventors of the genetically engineered mouse strain and a cancer pathologist at Cincinnati Children’s. He also noticed that severe COVID-19 disease clinical manifestations are very similar to those seen in transgenic laboratory mice created to faithfully mimic human secondary HLH in the lab. That preclinical laboratory research, some of it in collaboration with researchers in Wuhan, China, helped identify the drug ruxolitinib for treating secondary HLH. The anti-inflammatory drug is also used to treat other blood diseases, including leukemia.

During their work, Huang and researchers in China found other clinical studies involving other diseases where ruxolitinib also had worked well at quieting inflammation, and proceeded to successfully test the drug which dramatically reversed respiratory and multi-system inflammation in severely ill COVID-19 patients. A larger Phase III clinical trial RUXCOVID by Incyte and Novartis is now testing up to 400 severely ill COVID-19 patients with ruxolitinib, according to Huang, and preliminary clinical data from the study is expected during the summer.

“This is the first therapy we know of that appears to work effectively to quiet the cytokine storm and inflammation in severe COVID-19 disease, and there are no significant toxicities to patients who take the drug by two pills a day,” said Huang. “This is critical until we can develop and distribute enough effective vaccine to help prevent people from becoming infected.”

Related Links:
Cincinnati Children’s Hospital Medical Center


Print article
IIR Middle East

Channels

Critical Care

view channel
Image: Three dimensional measurement of the all-mesh thermistor (Photo courtesy of Shinshu University)

Ultraflexible, Gas-Permeable Thermistors to Pave Way for On-Skin Medical Sensors and Implantable Devices

On-skin medical sensors and wearable health devices are important health care tools that must be incredibly flexible and ultrathin so they can move with the human body. In addition, the technology has... Read more

Surgical Techniques

view channel
Image: Engineers have developed a process that enables soft robots to grow like plants (Photo courtesy of University of Minnesota)

Soft Robotic System Can Grow Like Plants to Allow Surgical Access to Hard-To-Reach Areas

Soft robotics is an emerging field where robots are made of soft, pliable materials as opposed to rigid ones. Soft growing robots can create new material and “grow” as they move. These machines could be... Read more

Patient Care

view channel
Image: The biomolecular film can be picked up with tweezers and placed onto a wound (Photo courtesy of TUM)

Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients

Conventional bandages may be very effective for treating smaller skin abrasions, but things get more difficult when it comes to soft-tissue injuries such as on the tongue or on sensitive surfaces like... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: Differentiated stapling technology for bariatric surgery (Photo courtesy of Standard Bariatrics)

Teleflex Completes Acquisition of Bariatric Stapling Technology Innovator

Teleflex Incorporated (Wayne, PA, USA), a leading global provider of medical technologies, has completed the previously announced acquisition of Standard Bariatrics, Inc. (Cincinnati, OH, USA), which has... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.